Biodesix enhances access to nodify lung® testing with launch of new blood draw method

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collecting blood specimens for nodify lung nodule risk assessment testing. the method uses the fda-cleared tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient's upper arm. blood-based nodify lung testing, comprised of the nodify cdt® and n.
BDSX Ratings Summary
BDSX Quant Ranking